St. Michael's Hospital
Toronto, Ontario, M5B 1W8, Canada
NCT Number: NCT02621307
The purpose of this study is to determine whether drinks containing Salvia hispanica L (Salba) or Flax lower postprandial blood glucose levels and improve appetite in healthy individuals.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Toronto, Ontario, M5B 1W8, Canada
Dietary fibre has been implicated in improving many risk factors associated with Type 2 Diabetes and Cardiovascular Disease (CVD). However, on average, Norther Americans consume less than half of the recommended amount set by health agencies. It has been proposed that the health benefits of dietary fibre may be attritbuted to rheological characteristics such as viscosity. Salvia hispanica L (Salba) and Flax are nutritionally similar. The primary objective of this research trial is to study the effects of Salba and Flax on postprandial glycemia and appetite in healthy individuals.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Salvia hispanica L
Other names: Glucose
Time frame: 2 Hours
At each visit, postprandial blood glucose will be measured via capillary blood samples, at 15, 30, 45, 60, 90, and 120 minutes after intake of test meals
Time frame: 2 Hours
At each visit, subjective satiety (how hungry/full you feel) will be measured via questionnaires, at 15, 30, 45, 60, 90, and 120 minutes after intake of test meals
Unity Health Toronto
Other
The Effect of Salba (Salvia Hispanica L) Versus Flax on Postprandial Blood Glucose Response and Subjective Appetite in Healthy Individuals
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04730882
Autoimmune Diseases, Diabetes Mellitus
Charlottesville, Virginia, United States
View Trial DetailsNCT06241976
Glucose Metabolism Disorders, Hyperglycemia
London, United Kingdom
View Trial DetailsNCT05528874
Appetitive Behavior, Behavior
Novara, Italy
View Trial DetailsNCT04163874
Autoimmune Diseases, Diabetes Mellitus
Montreal, Quebec, Canada
View Trial Details